Incyte stock faces pipeline uncertainty amid latest clinical trial setbacks in oncology portfolio

2026-04-05 17:56:48

Incyte Corporation’s shares are under pressure after its Phase 3 LIMBER-304 trial for ruxolitinib in myelofibrosis missed its primary endpoint, raising concerns about the company’s reliance on Jakafi sales. Despite diversification efforts with Opzelura and a strong balance sheet, intensifying competition and looming patent expirations for Jakafi in 2027-2028 create pipeline uncertainty and valuation challenges for the biotech firm. US investors are advised to monitor upcoming data readouts for potential inflection points.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.